COVID19: Ensuring the Quality, Resiliency, and Continuity of Breast Cancer Care During a Pandemic

Gain insights on how the COVID-19 pandemic is impacting breast cancer care along with expert input on treatment considerations to optimize management while limiting risk of exposure as new data emerge in this live Webinar, plus downloadable slides.


Overview of Breast Cancer Management During the COVID-19 Pandemic

  • Priorities for Surgical, Medical, and Radiation Oncology
  • Management Considerations by Subtype and Disease Stage

COVID-19 in Breast Cancer Patients

Question and Answer Session With the Faculty


Date / Time
Event Details


Harold Burstein, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Hope Rugo, MD

Professor of Medicine
Director, Breast Cancer and Clinical Trials Education
Division of Hematology/Oncology
Department of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Goal Statement
The goal of this activity is to provide a comprehensive, agile, and highly accessible educational curriculum designed to improve oncology healthcare professionals’ competence in providing effective personalized care for patients with breast cancer during the COVID-19 pandemic.

Target Audience
This program is intended for medical oncologists, pathologists, oncology nurses, pharmacists, and advanced practice providers in oncology who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply best practices for clinic/center preparedness to limit infection risk with SARS-CoV-2 across breast cancer patient populations
  • Understand the prevalence and clinical presentation of COVID-19 in breast cancer patients
  • Assess strategies to optimize treatment protocols on a personalized basis with special consideration toward differentiating between patients at high risk vs relatively lower risk of COVID-19 in the community, as well as intent of treatment (curative intent vs palliative intent) while balancing logistics of care with the need to practice physical distancing to mitigate exposure to SARS-CoV-2
  • Identify optimal protocols to manage adverse events associated with treatment approaches for breast cancer to help minimize exposure to SARS-CoV-2
  • Review best practice monitoring considerations for breast cancer patients receiving systemic therapy with known adverse events including interstitial lung disease and/or pneumonitis
  • Evaluate available and emerging clinical data on optimal management strategies for breast cancer patients with new respiratory symptoms/known COVID-19 exposure and management for patients without respiratory symptoms
  • Discuss the impact of clinical trial protocol modifications during the COVID-19 pandemic to determine if trials can safely and successfully continue once the pandemic has ended, as well as whether such modifications can accelerate patient enrollment
  • Identify resources for oncology healthcare professionals with tips on enhancing coping and enhancing mental and physical health during the COVID-19 pandemic


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-20-055-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.